ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Br…

ENHERTU Plus Pertuzumab Approved in the U.S. for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer ...

Dan Herbatschek, Ramsey Theory Group CEO, Evaluates the AI Hype with New Survey Results of Enterprise Leaders Showing the Four Hard Questions Being Asked Now

Dan Herbatschek’s new enterprise customer survey shows what CIOs, CISOs, and boards really want from AI in 2026: control, ...